Researchers from Rice University and the University of Texas MD Anderson Cancer Center have discovered potential new drugs that work in concert with other drugs to deliver a deadly one-two punch to leukemia.
Jun 30, 2022
0
65
Dysfunction involving an unusual type of thymocyte cell found in small amounts in every person may be the reason why some people develop a form of leukemia called T-cell acute lymphoblastic leukemia (T-ALL) that affects more ...
Jun 27, 2022
0
80
Arsenic seems to have a dual effect on carcinogenesis, according to a study recently published in Frontiers in Public Health.
Jun 20, 2022
0
2
Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children. The T-ALL form of leukemia that emerges from early T lineage cells has a poorer prognosis than B-lineage ALL. The prognosis for relapsed T-ALL ...
Jun 20, 2022
0
14
New research describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications—the so-called epigenetics—of a type of its genetic material: ...
Jun 9, 2022
0
10
Leukemia starts in cells that would normally develop into different types of blood cells. About 61,000 people in the U.S. are diagnosed each year, and depending on the type of leukemia and the age of the patient, five-year ...
Jun 8, 2022
0
27
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, ...
Jun 2, 2022
0
77
Survival has improved greatly in children with acute lymphocytic leukemia (ALL). But a certain form of ALL that occurs mostly in babies is still very lethal, with a survival rate below 50 percent: B-cell acute lymphoblastic ...
Jun 1, 2022
0
35
Imatinib, better known as Gleevec, was hailed as a "miracle" cancer drug when it entered the market in the early 2000s. Though it has been highly successful at treating early-stage chronic myeloid leukemia (CML)—a rare ...
Jun 1, 2022
0
150
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS), and increasingly in other diseases, but their mechanism of action is not clear. HMAs may affect many ...
May 26, 2022
0
18
